AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled Study
Phase 2
Withdrawn
- Conditions
- Neurofibromatosis Type 1Post-operativePlexiform Neurofibromas
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT05825365
Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI
Active, not recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 296
- Registration Number
- NCT05826366
- Locations
- 🇯🇵
Research Site, Yamaguchi, Japan
A PET Study to Determine Biodistribution and Binding Characteristics of [11C]AZ14132516 in Healthy Participants
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8
- Registration Number
- NCT05818514
- Locations
- 🇸🇪
Research Site, Solna, Sweden
An ADME Study of [14C]AZD0780 in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Cardiovascular Diseases
- Interventions
- Drug: AZD0780 tabletDrug: [14C]AZD0780 Solution for InfusionDrug: [14C]AZD0780 Oral Solution
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8
- Registration Number
- NCT05817461
- Locations
- 🇬🇧
Research Site, Ruddington, United Kingdom
Validating Artificial Intelligence Effectiveness Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule.
Active, not recruiting
- Conditions
- Lung Malignancy
- Interventions
- Other: Participant Cohort
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 700
- Registration Number
- NCT05817110
- Locations
- 🇹🇷
Research Site, Mersin, Turkey
A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Phase 2
Active, not recruiting
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- Other: Placebo
- First Posted Date
- 2023-04-12
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 175
- Registration Number
- NCT05809934
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations
Phase 2
Active, not recruiting
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2023-04-06
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT05801029
- Locations
- 🇹🇭
Research Site, Songkhla, Thailand
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Phase 1
Recruiting
- Conditions
- Ovarian CancerLung Adenocarcinoma
- Interventions
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 396
- Registration Number
- NCT05797168
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Elarekibep in Healthy Japanese Subjects
Phase 1
Terminated
- Conditions
- Healthy Subjects (Indication: Asthma)
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT05794672
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 22
- Registration Number
- NCT05790304
- Locations
- 🇸🇰
Research Site, Bratislava, Slovakia
© Copyright 2025. All Rights Reserved by MedPath